Pharmaceuticals

Pharmaceutical Gelatin Market Insights: Revenue Expected to Surpass $13.15 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceutical gelatin market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Pharmaceutical Gelatin Market?

The C5 complement inhibitors market size has experienced considerable expansion in recent years. It is forecast to increase from $6.91 billion in 2024 to $7.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.5%. The historical growth can be attributed to several factors, including the rising prevalence of rare and chronic diseases, an escalating demand for targeted therapies, increased awareness among healthcare providers, greater investment in research and development, and favorable reimbursement policies.

The C5 complement inhibitors market is projected to experience swift expansion in the coming years, with an anticipated valuation of $13.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.8%. Factors contributing to this growth during the forecast period include partnerships among pharmaceutical companies, improvements in healthcare infrastructure, substantial spending on healthcare, a rising need for novel therapies, and the growing occurrence of complement-mediated conditions. Key trends expected within this period encompass breakthroughs in biotechnology, increased funding for RNA-based approaches and gene therapies, enhancements in diagnostic instrumentation, the introduction of new treatments, and progress in monoclonal antibody therapeutics.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23334&type=smp

Which Growth Drivers Are Propelling The Pharmaceutical Gelatin Market?

The escalating incidence of chronic diseases is anticipated to drive the expansion of the C5 complement inhibitors market in the future. These enduring medical conditions progress gradually and persist over time, frequently necessitating continuous medical attention and management to avert complications. The rising prevalence of chronic diseases is largely influenced by lifestyle alterations such as an unhealthy diet, insufficient physical activity, smoking, and stress, all of which contribute to long-term health decline. C5 complement inhibitors benefit patients with chronic diseases by blocking the excessive activation of the complement system, thereby mitigating inflammation, preventing tissue damage, and improving outcomes in conditions such as PNH, aHUS, and other complement-mediated disorders. For example, in October 2022, a report from the World Heart Federation, a Switzerland-based non-profit organization, projected that cardiovascular disease-related deaths would climb from approximately 22.2 million by 2030, eventually reaching 32.3 million by 2050. Thus, the growing prevalence of chronic diseases is propelling the growth of the C5 complement inhibitors market.

Which Segmentation Factors Are Most Significant In The Pharmaceutical Gelatin Market Analysis?

The c5 complement inhibitors market covered in this report is segmented –

1) By Product: Long Acting C5 Inhibitors, Short Acting C5 Inhibitors

2) By Drug: Eculizumab, Ravulizumab, Other Drugs

3) By Route Of Administration: Intravenous, Subcutaneous, Oral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Paroxysmal Noctural Hemoglobuinuria, Atyptical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optics Spectrum Disorder, Other Applications

Subsegments:

1) By Long Acting C5 Inhibitors: Crovalimab, Pozelimab, Tesidolumab, Other Long-Acting C5 Inhibitors

2) By Short Acting C5 Inhibitors: Zilucoplan, Cemdisiran, Nomacopan, Other Short-Acting C5 Inhibitors

What New Opportunities Are Emerging From Trends In The Pharmaceutical Gelatin Market?

Companies operating within the C5 complement inhibitors market are concentrating on creating new treatments, including patient-administered C5 inhibitors, to broaden therapeutic choices for generalized myasthenia gravis. Such an inhibitor functions as a targeted therapeutic agent that blocks the complement C5 protein to decrease inflammation and immune-related harm, and is designed for patient self-administration to address conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. As an example, in October 2023, Union Chimique Belge (UCB) SA, a Belgium-based biopharmaceutical company, disclosed that Zilbrysq (zilucoplan) received approval from the Food and Drug Administration (FDA), a US-based government regulatory agency, for treating adults with generalized myasthenia gravis (gMG). This approval is specifically for patients who are anti-acetylcholine receptor (AChR) antibody-positive, which represents a prevalent variant of the illness. Zilbrysq is a once-daily, subcutaneous, and self-administered C5 complement inhibitor, providing a fresh therapeutic alternative for gMG patients. This approval bolsters UCB’s neurology portfolio, thereby extending the available treatment selections for those afflicted with autoimmune neuromuscular disorders.

Who Are The Most Influential Companies In The Pharmaceutical Gelatin Market?

Major companies operating in the c5 complement inhibitors market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis AG, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., UCB Pharma SA, Swedish Orphan Biovitrum AB(Sobi), Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Kira Pharmaceuticals, Biopharma PEG Scientific Inc., ProbeChem Biochemicals, InflaRx NV, Akari Therapeutics Plc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/c5-complement-inhibitors-global-market-report

Which Region Holds The Largest Share In The Pharmaceutical Gelatin Market Today?

North America was the largest region in the C5 complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c5 complement inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23334&type=smp

Browse Through More Reports Similar to the Global Pharmaceutical Gelatin Market 2025, By The Business Research Company

Ace Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795